Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations

Zhu, Jinxiu; Xie, Qiang; Zhong, Aihong; Le, Yuyin

doi:10.1097/cad.0000000000001186

Cited by 3 publications

(6 citation statements)

References 15 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ORR and DCR were 21.6 and 100%, respectively; these rates were higher than those of the patients in the 0303 clinical trial study (9.2 and 81%, respectively) (Han et al, 2018). The DCR (100%) in the present study was much higher than that of anlotinib monotherapy (67.5%) and pemetrexed monochemotherapy (65.5%) in elderly advanced NSCLC patients (Zhu et al, 2021). In addition, the median PFS was 8.4 months, which was longer than that of DEB-BACE treatment (7.4 months) (Liu et al, 2021) and that of anlotinib monotherapy in advanced NSCLC patients (5 months) (Wu et al, 2019).…”

Section: Discussioncontrasting

confidence: 63%

“…Anlotinib was recommended as the thirdline or further-line treatment for NSCLC and showed a significant effect on prolonged survival and tolerable toxicity. Many scholars recommend anlotinib as the first-or second-line treatment, not only the third-or further-line treatment regimen (Zhu et al, 2021). Zhong et al (2020) confirmed that PFS was longer when anlotinib was used in first-/second-line treatment than in thirdor further-line treatment of advanced NSCLC.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer

Liu

Zhang

Ren

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Aim: The aim of this study is to determine the efficacy and safety of the combination therapy of drug-eluting bead bronchial arterial chemoembolization plus anlotinib oral administration in the treatment of non-small-cell lung cancer (NSCLC).Methods: Consecutive data from 51 patients with advanced NSCLC were retrospectively collected from February 2018 to August 2019. All patients underwent drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) followed by anlotinib treatment. Overall survival (OS) and progression-free survival (PFS) were calculated and analyzed using the Kaplan–Meier method and log-rank test, and factors associated with OS and PFS were assessed by a Cox proportional hazards test. Treatment response at 30 days was assessed by enhanced computed tomography (CT), and then the objective response rate (ORR) and disease control rate (DCR) were calculated. Treatment-related adverse events (TRAEs) were also evaluated.Results: The median OS was 18.4 months (95% CI, 16.6–20.2 months), and the median PFS was 8.4 months (95% CI, 6.2–10.6 months). The ORR and DCR for the whole cohort were 21.6 and 100%, respectively, at 30 days after the first cycle of treatment. Most of the treatment-related adverse reactions were mild and moderate and included anorexia, hypertension, fatigue, and hand-foot syndrome. Only eight (15.7%) patients developed grade 3 TRAEs. No deaths or other serious adverse reactions occurred. Both TNM stage and brain metastasis were independent risk factors for OS and PFS.Conclusion: DEB-BACE concomitant with anlotinib has promising efficacy and tolerable toxicity in patients with advanced NSCLC.

show abstract

Section: Discussioncontrasting

confidence: 63%

Section: Discussionmentioning

confidence: 93%

Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer

Liu

Zhang

Ren

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…There have also been more studies of anlotinib as a first-line treatment in the last 2 years, and most of these studies have adopted the combination therapy model. The latest clinical analysis of first-line therapy in elderly patients with advanced lung adenocarcinoma without driver gene mutations showed similar median PFS (3.0 m vs. 2.8 m) and OS (7.0 m vs. 7.0 m) in the anlotinib group and the chemotherapy group (P > 0.05), and there was no significant difference in ORR (17.5 vs. 15%) or DCR (67.5 vs. 65.5%) between both treatment groups (23). The other studies have shown that, for driver gene-negative NSCLC patients, the median PFS in the anlotinib combined with chemotherapy group was 1.54 months longer than that in the chemotherapy group (9.38 months vs. 7.84 months, P < 0.05), and the median OS in the anlotinib combined with chemotherapy group was longer as well (11.52 months vs. 10.46 months), but the difference was not statistically significant (P > 0.05) (24).…”

Section: Discussionmentioning

confidence: 88%

“…A study on inoperable NSCLC patients indicated that the median PFS of sequential chemoradiotherapy patients was 10.8 months, but grade 3 acute esophagitis occurred in four of 78 patients (5%) ( 25 ). As shown in Table 2 ( 18 , 23 , 26 ), anlotinib is promising for the first-line treatment for NSCLC with its median PFS range of 3.0 to 15.0 months.…”

Section: Discussionmentioning

confidence: 99%

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report

Wang

Zhou

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approved for the standard third-line treatment for NSCLC in China. Herein we report an elderly NSCLC patient without any driver gene mutations who was undergoing anlotinib as a front-line treatment and who achieved long-term survival.Case summaryThe 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1).ConclusionThis patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy.

show abstract

“…In 2018, National Medical Products Administration (NMPA) officially approved anlotinib monotherapy based on ALTER0303 in patients with advanced NSCLC progressing after second-line or further treatment, providing a new choice for Chinese patients. Recently, some retrospective studies demonstrated the effectiveness and safety of anlotinib in Chinese elderly patients with NSCLC as a first-line therapy setting ( 20 , 21 ), suggesting that anlotinib could be used as a first-line treatment in Chinese elderly NSCLC patients.…”

Section: Introductionmentioning

confidence: 99%

Anlotinib in Chinese patients aged ≥70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial

Zhao,

Li,

Hou

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundBased on pharmacoeconomics, drug availability and actual treatment, optimal treatment regimens for Chinese non-small-cell lung carcinoma (NSCLC) patients over 70 years old are needed.MethodsThis multicenter, single-arm pilot trial enrolled patients with advanced non-squamous NSCLC who refused systemic chemotherapy. Eligible patients received anlotinib (12 mg/day, d1-14, Q3W) until disease progression, intolerant toxicities, or withdrawal from the study. The primary endpoint was progression-free survival (PFS).ResultsForty-nine patients were screened between January 2019 and September 2021, of whom 40 patients were eligible. The median age was 76 years. With a median follow-up period of 16.20 (95% CI: 8.77, 25.10) months, the median PFS was 5.45 months (95% CI: 3.52-9.23) and the median overall survival was 10.32 months (95% CI: 6.44-12.78). Three patients achieved a partial response and 34 had stable disease, with an objective response rate of 7.5% and a disease control rate of 92.5%. Thirty-three (82.5%; 33/40) patients reported treatment-related adverse events (TRAEs) of any grade, and the incidence rate of grade ≥3 TRAEs was 35% (14/40). The most common grade ≥3 TRAEs were hypertension (4/40; 10.0%), hand-foot syndrome (3/40; 7.5%), and proteinuria (2/40; 5.0%).ConclusionAnlotinib treatment was feasible and safe in Chinese elderly patients with advanced non-squamous NSCLC who did not receive any systemic chemotherapy.

show abstract

Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations

Cited by 3 publications

References 15 publications

Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer

Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report

Anlotinib in Chinese patients aged ≥70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial

Contact Info

Product

Resources

About